CJC-1295 No DAC + Ipamorelin Blend Research: Dual-Receptor GH Axis Combination

The CJC-1295 No DAC + Ipamorelin blend is the most frequently used combination preparation in growth hormone axis research. It provides simultaneous activation of two distinct GH-releasing receptor systems on pituitary somatotrophs — GHRHR (via CJC-1295 No DAC) and GHS-R1a (via Ipamorelin) — through entirely different intracellular signalling pathways that produce additive or superadditive GH release when co-activated.

For complete mechanistic coverage of each compound, see the dedicated guides: Ipamorelin Research and CJC-1295 (No DAC) Research. This guide focuses on the combination research design and mechanistic synergy.

Dual Receptor Activation: The Pharmacological Rationale

GHRHR (GH Releasing Hormone Receptor) is a class B GPCR (structurally related to receptors for glucagon, GLP-1, and PTH) that couples to Gs. CJC-1295 No DAC activation raises intracellular cAMP via adenylyl cyclase, activating PKA. PKA phosphorylates CREB and other transcription factors driving GH gene transcription, and also promotes secretory granule mobilisation.

GHS-R1a (Growth Hormone Secretagogue Receptor 1a) is a class A GPCR that couples to Gq/11. Ipamorelin activation triggers phospholipase C, generating IP3 (calcium release from ER) and DAG (PKC activation). The calcium signal drives immediate secretory granule exocytosis.

These two pathways — cAMP/PKA and IP3/calcium/PKC — activate GH release through distinct and complementary mechanisms. Research has established that simultaneous activation of both receptors produces greater GH release than either alone, with some published data suggesting superadditive (synergistic rather than merely additive) effects.

Somatostatin Suppression: Ipamorelin's Additional Contribution

Beyond direct GHS-R1a agonism, Ipamorelin — like native ghrelin — also suppresses somatostatin release from hypothalamic neurons. Somatostatin is the primary inhibitory tone on pituitary GH secretion; its removal amplifies GH responsiveness to GHRHR stimulation from CJC-1295 No DAC. This additional mechanism explains part of the synergy observed when combining Ipamorelin with GHRH-axis peptides.

Pulsatile GH Research

Both CJC-1295 No DAC and Ipamorelin have plasma half-lives of approximately 30 minutes, producing discrete GH pulses rather than sustained GH elevation. This pulsatile pattern is important for studying pulse-frequency and pulse-amplitude dependent aspects of GH biology — including downstream IGF-1 production, tissue anabolic responses, and metabolic effects of GH pulsatility.

Published Research References

GH Pulse Characterisation

When using the CJC-1295 No DAC + Ipamorelin blend for pulsatile GH research, the key measurable endpoints are:

GH pulse amplitude. Peak GH concentration following administration, typically measured by GH ELISA in plasma samples collected at 15-30 minute intervals. The combination produces higher peak GH than either compound alone in published animal model research.

GH pulse duration. Time from GH peak to return to baseline. Both compounds have approximately 30 minute half-lives, producing GH pulses of similar duration but different amplitude than either compound alone.

IGF-1 production. Downstream hepatic IGF-1 production measured at 4-8 hours post-administration provides an integrated readout of GH pulse-driven anabolic signalling. For comparing pulsatile (No DAC combination) versus sustained (With DAC variants) GH stimulation effects on IGF-1, this endpoint is particularly informative.

Comparing No DAC Combination with Individual Components

The combination's advantage — amplified pulsatile GH with somatostatin suppression — explains its position as the most widely studied GH secretagogue combination in published GH axis pharmacology research. Individual components are available from Signal Labs for comparative single-compound studies.

For laboratory and analytical research purposes only. Not for human or veterinary use.

Related: Ipamorelin (individual) | CJC-1295 No DAC (individual) | GHRP-2
View CJC-1295 + Ipamorelin Blend product and buy →

Dual-Receptor Synergy: Mechanistic Evidence

The synergistic GH release from combining GHRHR and GHS-R1a stimulation is supported by published electrophysiology and pharmacology data. The two receptor systems activate GH secretion through complementary intracellular pathways:

CJC-1295 No DAC → GHRHR → Gs → cAMP ↑ → PKA → CREB phosphorylation (transcription) + L-type Ca2+ channel phosphorylation (exocytosis)

Ipamorelin → GHS-R1a → Gq/11 → PLCbeta → IP3 → ER Ca2+ release + DAG → PKC (exocytosis)

Published data from combined GHRH + GHRP administration studies (using native GHRH and GHRP-6 or GHRP-2 as precursor compounds to CJC-1295/Ipamorelin) documented superadditive GH release — greater than the sum of individual compound effects. The mechanistic basis for this superadditivity is the complementary signal convergence: both cAMP/PKA and IP3/calcium are required for optimal GH granule exocytosis, and activating both simultaneously through different receptors achieves synergistic exocytosis.

Additionally, Ipamorelin (like ghrelin) inhibits somatostatin release from hypothalamic periventricular neurons. Somatostatin is the endogenous GH inhibitor — its suppression by GHS-R1a activation removes the brake on GHRHR-mediated GH release, further amplifying the combined response.

Pulsatile GH Research Paradigms

For research specifically examining pulse amplitude and frequency effects on downstream biology, the CJC-1295 No DAC + Ipamorelin blend provides the most physiologically relevant pulsatile stimulation paradigm among GHRH/GHRP combinations.

Research designs for pulsatile GH studies include:

Multiple pulse paradigm: Administer the blend at defined intervals (mimicking physiological 3-4 hour pulsatile patterns) and measure GH, IGF-1, and downstream gene expression at multiple timepoints. Compare with single-pulse administration to examine cumulative versus single-exposure effects.

Pulse frequency dependence: Vary the interval between blend administrations (1-hour, 3-hour, 6-hour intervals) to examine whether GH responses are maintained across frequencies or show time-dependent changes in amplitude, reflecting receptor resensitisation kinetics.

Downstream IGF-1 kinetics: Measure hepatic IGF-1 mRNA and plasma IGF-1 protein following defined pulsatile stimulation patterns to characterise the GH pulse-to-IGF-1 translation curve — a research endpoint connecting GH pulse biology to downstream anabolic signalling.

Frequently Asked Questions

What is the research rationale for using 5mg/5mg ratio in the blend rather than other ratios?
The 5mg/5mg ratio provides equivalent mass of each compound but does not imply equivalent molar concentration — CJC-1295 No DAC (MW 3367.9) is significantly larger than Ipamorelin (MW 711.85), so 5mg CJC-1295 No DAC provides approximately 1.5 nanomoles while 5mg Ipamorelin provides approximately 7 nanomoles. The molar ratio in the reconstituted blend is approximately 1:5 (CJC-1295 No DAC:Ipamorelin). Research requiring specific molar ratios should calculate reconstitution volumes accordingly for each compound using the individual products rather than the blend.

How does the CJC-1295 No DAC + Ipamorelin blend compare with GHRH + GHRP-6 in published literature?
The vast majority of published research on GHRHR + GHS-R1a dual stimulation used native GHRH(1-29) (Sermorelin) and GHRP-6 or GHRP-2, rather than the stabilised CJC-1295 No DAC and selective Ipamorelin. The published data from these earlier compound combinations provides the pharmacological framework (synergistic GH release, somatostatin suppression, dual-pathway intracellular signalling) that applies mechanistically to the CJC-1295 No DAC + Ipamorelin combination. Researchers can use published GHRH + GHRP studies as reference frameworks while recognising that the stabilised, selective compounds (CJC-1295 No DAC, Ipamorelin) provide improved pharmacological tools compared to the historical reference compounds.

Browse all Signal Labs research peptides | Peptide storage guide | Reconstitution guide